No Data
The Analyst Verdict: Vericel In The Eyes Of 7 Experts
CCORF Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $57
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $55
TD Cowen Maintains Vericel(VCEL.US) With Buy Rating, Raises Target Price to $60
Buy Rating on Vericel: Expanding Market Reach With FDA-Approved MACI Arthro Platform
Vericel Says US FDA Approves SBLA for Tissue Restoring Knee Repair Treatment - Shares Up Pre-Bell
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
No Data
